The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer
Open accessAbstract
An effective, nontoxic, tumor-specific immunotherapy is the ultimate goal in the battle against cancer, especially the metastatic disease. Checkpoint blockade-based immunotherapies have been shown to be extraordinarily effective but benefit only the minority of patients whose tumors have been pre-infiltrated by T cells. Here, we show that Zn-pyrophosphate (ZnP) nanoparticles loaded with the photosensitizer pyrolipid (ZnP@pyro) can kill tumor cells upon irradiation with light directly by inducing apoptosis and/or necrosis and indirectly by disrupting tumor vasculature and increasing tumor immunogenicity. Furthermore, immunogenic ZnP@pyro photodynamic therapy (PDT) treatment sensitizes tumors to checkpoint inhibition mediated by a PD-L1 antibody, not only eradicating the primary 4T1 breast tumor but also significantly preventing metastasis to the lung. The abscopal effects on both 4T1 and TUBO bilateral syngeneic mouse models further demonstrate that ZnP@pyro PDT treatment combined with anti-PD-L1 results in the eradication of light-irradiated primary tumors and the complete inhibition of untreated distant tumors by generating a systemic tumor-specific cytotoxic T cell response. These findings indicate that nanoparticle-mediated PDT can potentiate the systemic efficacy of checkpoint blockade immunotherapies by activating the innate and adaptive immune systems in tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Photodynamic therapy for cancer
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1071 · Cited by 6,758
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Cited by
Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer Therapy
Wu, M., & Yang, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606134 · Cited by 2,285
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine
Overchuk, M., Weersink, R. A., Wilson, B. C., & Zheng, G. (2023) · ACS Nano · doi:10.1021/acsnano.3c00891 · Cited by 1,323
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Self-citationCancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Emerging combination strategies with phototherapy in cancer nanomedicine
Xie, Z., Fan, T., An, J., Choi, W., Duo, Y., Ge, Y., Zhang, B., Nie, G., Xie, N., Zheng, T., et al. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00215a · Cited by 716
Engineering nanomedicine for glutathione depletion-augmented cancer therapy
Xiong, Y., Xiao, C., Li, Z., & Yang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00718h · Cited by 692
Li, Z., Lai, X., Fu, S., Ren, L., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 680
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
Yue, W., Chen, L., Yu, L., Zhou, B., Yin, H., Ren, W., Liu, C., Guo, L., Zhang, Y., Sun, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09760-3 · Cited by 590
Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy
Deng, X., Shao, Z., & Zhao, Y. (2021) · Advanced Science · doi:10.1002/advs.202002504 · Cited by 590
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Alzeibak, R., Mishchenko, T. A., Shilyagina, N. Y., Balalaeva, I. V., Vedunova, M. V., & Krysko, D. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001926 · Cited by 565
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 467
Combining Nanomedicine and Immunotherapy
Shi, Y., & Lammers, T. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00148 · Cited by 457
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Gunaydin, G., Gedik, M. E., & Ayan, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.686303 · Cited by 402
Chen, H.-Y., Deng, J., Wang, Y., Wu, C.-Q., Li, X., & Dai, H.-W. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.05.028 · Cited by 402
Xu, J., Yang, P., Sun, M., Bi, H., Liu, B., Yang, D., Gai, S., He, F., & Lin, J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00944 · Cited by 398
Chen, Z., Liu, L., Liang, R., Luo, Z., He, H., Wu, Z., Tian, H., Zheng, M., Ma, Y., & Cai, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b04371 · Cited by 363
Meng, Z., Zhou, X., Xu, J., Han, X., Dong, Z., Wang, H., Zhang, Y., She, J., Xu, L., Wang, C., et al. (2019) · Advanced Materials · doi:10.1002/adma.201900927 · Cited by 362
Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy
Ng, C. W., Li, J., & Pu, K. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804688 · Cited by 349
Xie, W., Deng, W.-W., Zan, M., Rao, L., Yu, G.-T., Zhu, D.-M., Wu, W.-T., Chen, B., Ji, L.-W., Chen, L., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b03788 · Cited by 343
Song, W., Kuang, J., Li, C.-X., Zhang, M., Zheng, D., Zeng, X., Liu, C., & Zhang, X.-Z. (2018) · ACS Nano · doi:10.1021/acsnano.7b09112 · Cited by 314
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Liang, R., Liu, L., He, H., Chen, Z., Han, Z., Luo, Z., Wu, Z., Zheng, M., Ma, Y., & Cai, L. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.051 · Cited by 300
Yu, G., Zhao, X., Zhou, J., Mao, Z., Huang, X., Wang, Z., Hua, B., Liu, Y., Zhang, F., He, Z., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04400 · Cited by 299
Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 288
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S. N., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 281
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
Hartshorn, C. M., Bradbury, M. S., Lanza, G. M., Nel, A. E., Rao, J., Wang, A. Z., Wiesner, U. B., Yang, L., & Grodzinski, P. (2018) · ACS Nano · doi:10.1021/acsnano.7b05108 · Cited by 258
Zhang, S., Wang, J., Kong, Z., Sun, X., He, Z., Sun, B., Luo, C., & Sun, J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121433 · Cited by 255
Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy
Gao, J., Wang, W.-Q., Pei, Q., Lord, M. S., & Yu, H.-J. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0400-z · Cited by 203
Current Challenges and Opportunities of Photodynamic Therapy against Cancer
Huis in ‘t Veld, R. V., Heuts, J., Ma, S., Cruz, L. J., Ossendorp, F. A., & Jager, M. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020330 · Cited by 159
Han, W., Duan, X., Ni, K., Li, Y., Chan, C., & Lin, W. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121315 · Cited by 103
Self-citationDelivery Strategies for Immune Checkpoint Blockade
Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90
Metadata
- Authors
- Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-12-15
- Volume
- 138
- Issue
- 51
- Pages
- 16686-16695
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2558284519
- Cited by
- 458
- References
- 78
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.